COMP <GO>
NEOG vs LLY // RETURN ON INVESTED CAPITAL (ROIC)
Neogen Corporation (NASDAQ) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: NEOG 1
— LLY 10
▲ RETURN ON INVESTED CAPITAL (ROIC) LEADER: LLY
LAST: $12.26 (+1.16%) • MKT CAP: $2.68B
roic
-0.60%
LAST: $1,373.70 (+6.63%) • MKT CAP: $1.29T
roic
32.36%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (NEOG VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | NEOG | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 46.90% | 83.64% | -36.74 | LLY | /gross-margins <GO> |
| Return on Invested Capital (ROIC) ACTIVE | -0.60% | 32.36% | -32.96 | LLY | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 36.4x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 3.11% | 2.30% | +0.81 | NEOG | /fcf-yield <GO> |
| Operating Margin | -2.50% | 40.21% | -42.71 | LLY | /operating-margins <GO> |
| Net Profit Margin | -0.90% | 31.90% | -32.80 | LLY | /net-margins <GO> |
| Revenue Growth (YoY) | -2.70% | 45.51% | -48.21 | LLY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.49% | -0.49 | LLY | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 1.45 | 9.29 | -7.84 | LLY | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 9/9 | -2.00 | LLY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 6.77% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 45.3 | 66.6 | -21.35 | LLY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.51 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 26.3x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $2.68B | $1.29T | -$1.29T | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | NEOG REV | LLY REV | NEOG GROSS % | LLY GROSS % | NEOG FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $870.4M | $65.18B | 46.9% | 83.0% | $83.2M | $16.81B |
| FY 2024 | $894.7M | $45.04B | 47.1% | 81.3% | $58.2M | $8.82B |
| FY 2023 | $924.2M | $34.12B | — | 79.3% | $35.3M | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
NEOG // BETA —
LLY // BETA 0.51